Magenta Therapeutics, Inc. (MGTA) News
Filter MGTA News Items
MGTA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MGTA News Highlights
- For MGTA, its 30 day story count is now at 2.
- Over the past 20 days, the trend for MGTA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CCO and RYAN are the most mentioned tickers in articles about MGTA.
Latest MGTA News From Around the Web
Below are the latest news stories about Magenta Therapeutics Inc that investors may wish to consider to help them evaluate MGTA as an investment opportunity.
What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?A look at the shareholders of Magenta Therapeutics, Inc. ( NASDAQ:MGTA ) can tell us which group is most powerful... |
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data PlatformBusiness combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland, CEO of GeneDx and former CCO of Invitae, to join Sema4 as Co-CEO, alongside Eric Schadt, PhD, and become a member of Sema4’s Board of Directors Director Jason Ryan, former CFO of Foundation Medicine, to assume role of Executive Chair of Sema4’s Board o |
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022CAMBRIDGE, Mass., January 10, 2022--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today highlighted progress across its portfolio of targeted conditioning and stem cell mobilization programs and set out its milestone expectations for both clinical and preclinical data in 2022. These updates will also be discussed during a webcast presentation at the 40th Annual |
Magenta rises 6% on Goldman Sachs upgrade with $8 target price (NASDAQ:MGTA)Goldman Sachs analyst Madhu Kumar upgraded Magenta Therapeutics (MGTA) to Buy from Neutral with a price target ((PT)) of $8, up from $7. Shares up 6% premarket at $4.73 |
Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology ConferenceCAMBRIDGE, Mass., January 05, 2022--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following January investor conferences: |
Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of DirectorsLEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Dr. Jeffrey S. Humphrey, MD, Chief Medical Officer of Magenta Therapeutics to its Board of Directors. Dr. Humphrey is an accomplished clinical researcher and drug developer who has shepherded numerous drugs through all phases of development from pre-IND to post-lau |
Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual MeetingCAMBRIDGE, Mass., December 14, 2021--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today highlighted three presentations made at the 2021 American Society of Hematology (ASH) Annual Meeting. |
Analysts Expect Magenta Therapeutics, Inc. (NASDAQ:MGTA) to Announce -$0.36 Earnings Per ShareWall Street analysts expect Magenta Therapeutics, Inc. (NASDAQ:MGTA) to post ($0.36) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Magenta Therapeutics earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.47). Magenta Therapeutics posted earnings of ($0.38) per share during the same quarter last year, [] |
Vanguard Group Inc. Buys 120,322 Shares of Magenta Therapeutics, Inc. (NASDAQ:MGTA)Vanguard Group Inc. lifted its stake in Magenta Therapeutics, Inc. (NASDAQ:MGTA) by 8.5% in the second quarter, Holdings Channel.com reports. The fund owned 1,543,793 shares of the companys stock after purchasing an additional 120,322 shares during the period. Vanguard Group Inc.s holdings in Magenta Therapeutics were worth $15,098,000 as of its most recent filing with [] |
Geode Capital Management LLC Has $4.92 Million Stock Position in Magenta Therapeutics, Inc. (NASDAQ:MGTA)Geode Capital Management LLC boosted its holdings in shares of Magenta Therapeutics, Inc. (NASDAQ:MGTA) by 24.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 503,191 shares of the companys stock after buying an additional 99,393 shares during the period. Geode Capital Management LLC owned [] |